- Home
- OPRA vs RAPP Comparison
OPRA vs RAPP Comparison
Compare OPRA & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPRA | RAPP |
|---|---|---|
| Founded | 1996 | 2022 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | OPRA | RAPP |
|---|---|---|
| Price | $18.60 | $41.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $21.50 | ★ $48.50 |
| AVG Volume (30 Days) | 317.0K | ★ 354.0K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.29 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.71 | $13.64 |
| 52 Week High | $21.06 | $44.28 |
Technical Indicators
Market Signals| Indicator | OPRA | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 53.14 |
| Support Level | $18.10 | $38.55 |
| Resistance Level | $19.43 | $43.89 |
| Average True Range (ATR) | 0.68 | 2.36 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 33.50 | 52.65 |
Price Performance
Historical ComparisonAbout OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.